Evotec (ETR:EVT) Shares Down 0.7% – What’s Next?

Evotec SE (ETR:EVT) shares dropped 0.7% on Wednesday . The company traded as low as €4.06 and last traded at €4.12. Approximately 452,587 shares were traded during trading, a decline of 67% from the average daily volume of 1,360,000 shares. The stock had previously closed at €4.15.

Evotec Stock Performance

The company’s 50-day simple moving average is €5.59 and its 200-day simple moving average is €5.83. The stock has a market capitalization of $811.76 million, a price-to-earnings ratio of -4.73, a PEG ratio of 0.98 and a beta of 1.12. The company has a current ratio of 2.12, a quick ratio of 2.97 and a debt-to-equity ratio of 60.57.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic.